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ABSTRACT 
 
Soluble forms of nonclassical human leukocyte antigen (HLA)-G have recently been 
suggested as immunomodulatory factors in multiple sclerosis (MS). HLA-G inhibits the 
effecter function of T cells and natural killer (NK) cells. Also regulatory T cells (Treg) are 
considered as pivotal players in MS pathogenesis. Thus, we aimed to evaluate the presence of 
HLA-G molecules and Treg cells in Relapsing-Remitting Multiple Sclerosis (RRMS) patients 
and compare it to healthy controls.  
Patients with RRMS (n=205, mean age=31.32±8.53) and healthy subjects (n=205, mean 
age=32.2±7.48) were studied. The patients subgrouped to untreated and treated with 
Interferon beta. Then sHLA-G levels (sHLA-G1 and sHLA-G5) were measured using 
ELISA method. Treg (CD4+CD25+ Foxp3+) cells in patients who had sHLA-G>10 U/ml 
were characterized by using flow cytometry.  
Our data showed that there was no significant differences between RRMS patients and 
healthy controls in  sHLA-G concentration (p>0.05). Treg cell frequencies were higher in the 
patients who had sHLA-G >10 U/ml compared to healthy subjects (p<0.05). 
Collectively, there was significant correlation between sHLA-G and frequency of Treg 
cells in treated RRMS patients and healthy individuals. It seems that high level sHLA-G has 
been instrumental in raising frequency of Treg cells in treated patients and could be 
associated with remission of MS disease.   
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INTRODUCTION 
 
Multiple sclerosis (MS) is one of the most 
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important forms of the central nervous system (CNS) 
autoimmune inflammatory disorder. T cells play a 
pivotal role in development of complex events of MS. 
Currently, genetic, environmental factors and immune 
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deregulation have been identified as major factors in 
the pathogenesis of MS.  The key adventure is breakage 
of immune tolerance due to CNS self-antigens in 
genetically predisposed individuals.
1-3
 Through this 
breakage myelin damag is triggered by the activation of 
infiltrating autoreactive T helper cells (Th1). The 
predominance of Th1 cells and their related cytokines 
in relapse events of MS is in paralle with insuficiently 
counterbalanced Th2 cells. Indeed, dominance of Th2 
cells and their cytokines are seen in the stable phase of 
disease.
4
 Classically, MS is categorized in three distinct 
subtypes of relapsing remitting (RR), secondary 
progressive (SP), and primary progressive (PP).
5
 
Relapse is associated with a sudden worsening of 
symptoms that lasts 24 hours or develops new 
neurological signs in a month.
6
 Among the influencing 
factors of the disease, human leukocyte antigen 
G (HLA-G) is considered as one of the basic immune 
molecules. HLA-G has a limited polymorphism.
7
 
Messenger RNA of HLA-G molecule endures 
alternative splicing which leads to the formation of four 
membrane-anchored (HLA-G1, G2, G3 and G4) and 
three secreted (HLA-G5, G6, and G7) molecule 
structures.
8,9
 HLA-G1 molecules can interact with T 
cells, B cells, natural killer (NK) cells, and Antigen 
Presenting cells (APC) directly by their receptors and 
employ its immunotolerant tasks at various stages of 
the immune response.
10
 Major isoforms of sHLA-G  
antigen are HLA-G1 and HLA-G5 and Soluble HLA-G 
(sHLA-G) molecules are derived from shedding of 
membrane-bound HLA-G1 and secretion of HLA-G5 
isoforms.
11
 The immunesuppressive activities of these 
HLA-G antigens are mediated through binding to their 
receptors.
12
 It has been demonstrated that peripheral 
blood monocytes are major cells secreting HLA-G5 
antigens.
13
 HLA-G antigen, in both soluble and 
membrane-anchored forms exhibit effector functions 
on T cells and NK cells through interaction with 
immunoglobulin-like transcript (ILT) receptors as ILT2 
(LILRB1/CD85j), ILT4 (LILRB2/CD85d), KIR2DL4 
(CD158d) and CD8a-chain.
14-18
 Since anti-
inflammatory cytokines such as interleukin-10 (IL-10) 
enhance HLA-G expression and consequently up-
regulate IL-10 secretion, HLA-G antigens are 
suggested to act as immunomodulatory molecules by 
induction of an immune deviation from Th1 to Th2 
polarized responses.
19
 Regarding MS, the expression of 
HLA-G antigens is shown on the microglia, 
macrophages and endothelial cells within and in the 
lesions. In microglial cells of MS lesions, HLA-G 
expression was seen to be enhanced by Th1 
proinflammatory cytokines. In addition, low levels of 
sHLA-G is associated with enhanced risk of 
autoimmunity.
10
 
Besides, regualtory T cells (Treg) play a pivotal role 
in the pathogenesis of MS and its different disease 
courses, disease activity and response to various 
treatment modalities.
20
 Treg cells (CD4
+
 CD25
+
 
Foxp3
+)
 are an essential component of the immune 
response to induce peripheral tolerance  and also play 
an important role in balance between pro and anti-
inflammatory responses
21
 Both sHLA-G and Treg cells 
have modulator properties in the immune system. 
Therefore, the aim of this study was to assess whether 
serum sHLA-G isoforms were related to the frequency 
of CD4
+
 CD25
+
 FOXP3
+
 (Treg) cells in RRMS patients 
and healthy controls.  
 
MATERIALS AND METHODS 
 
Patients 
A total of 205 patients (mean age=31.32±8.53) who 
were referred to MS clinic with the diagnosis of 
definite RRMS in stable phase according to the 
classification of McDonald (2001) were enrolled in this 
study.
 
All patients were undergoing Expanded 
Disability Status Scale (EDSS) assessment and brain 
Magnetic resonance imaging (MRI) on a regular basis 
and they also completed informed consent form. All 
RRMS patients were in clinical remission at the time of 
blood collection. Seventy three patients were untreated 
(no immunomodulatory drugs), whereas the other 
patients were under treatment with interferon-β1a (IFN-
β). Healthy individuals (n=205, mean age=32.2±7.48) 
of blood donors (control groups) were also included in 
this research. This study was approved by the ethical 
committee of Tarbiat Modares University that it 
conforms to the provisions of the Declaration of 
Helsinki in 1995 (as revised in Edinburgh 2000). 
 
sHLA-G Assay 
Firstly peripheral blood samples were allowed to 
clot and then were centrifuged (for 10 min, 2400 x g). 
Serums were frozen immediately at -20°C. Then, levels 
of sHLA-G (sHLA-G1 and sHLA-G5) were determined 
using a commercial ELISA kit (Glory Science, USA). 
All sample tests were performed in duplicates. The 
Optical density (OD) of samples was measured at 450 
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nm by Dynatech plate reader. The quantity of sHLA-G 
was determined by constructing a calibration curve of 
HLA-G1 and sHLA-G5. 
 
CD4
+
 CD25
+
 FOXP3
+ 
Treg
 
Cell Isolation  
Peripheral blood samples from 21 patients and 7 
healthy individuals who had sHLA G≥10 U/ml (out of 
205 participants) were screened for the presence of 
CD4
+
 CD25
+
 FOXP3
+ 
Treg cells by flow cytometry. 
Since, CD4
+ 
T cells that co-express high amounts of 
CD25 exert regulatory functions, Treg counts were 
characterized as the frequency of FITC-CD4 positive 
cells with the highest PE-CD25 and PE-CY5-FOXP3 
fluorescence intensity. Three-color flow cytometry was 
used to identify and quantify CD4
+
CD25
high
 Foxp3
+ 
Treg cells in patients treated with IFN-β vs. healthy 
controls (Dot plots one of the RRMS patients, a control 
group and isotype control are shown in Figure 1. Cell 
viability was assessed using Trepan blue exclusion 
more than 95%.  
Human Peripheral Blood Mononuclear Cells 
(PBMCs) were isolated using Ficoll density gradient 
centrifugation (Histopaque, Sigma-Aldrich). Treg cells 
were stained using human Treg cell kit (anti-human 
FITC-CD4, PE-CD25, PE-CY5-FOXP3, FITC-IgG2a 
and PE-IgG2a. BD eBioscience, Belgium) PBMCs 
were stained (30 min ,4
◦
c) washed and then analyzed 
using flow cytometry (FACS Calibur ,BD Biosciences) 
for phenotypic analysis of cells. In order to stain intra-
cellular compartment of FOXP3, cells were fixed and 
permeabilized before adding anti-human FOXP3 (PE-
CY5-clone PCH101, eBioscience) according to the 
protocol. Data analyses were performed using Cell 
Quest software (10.5.3) (BD Biosciences).  
 
 
 
 
Figure 1. A representative plot  of CD25hi Foxp3+ Treg cells  in a patient and control. 
The x-axis of each dot plots represents specific fluorescence of  PE-CY5-Foxp3+; the y-axis represents specific fluorescence of 
PE -CD25+. Quadrants were set using appropriate isotype controls for each intra- and extracellular antibody. Peripheral 
Tregs were identified as CD25 hi FOXP3+ cells in CD4+ lymphocytes gate. 
 
 
Statistical Analysis 
We used ANOVA test for  comparison of 
differences of sHLA-G levels among  three gruops and 
effect of age on sHLA-G level. Kruskal-Wallis test was 
used to evaluate the effect of age on the Treg frequency 
and comparison of differences of Treg  cells among the 
three groups. We also applied Mann-Whitney test for 
comparison of Treg frequency and Tukey test for 
comparison of sHLA-G levels between the two groups. 
Moreover, data were assessed for the associations of 
age, sHLA-G and Treg values using Pearson’s 
correlation coefficient. The SPSS software (version 17) 
was used to calculate statistical significance. 
Differences were considered significant when p<0.05. 
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RESULTS 
 
Demographic characteristics is shown in Table 1. 
Laboratory Findings include the mean value of sHLA-
G and CD4
+
 CD25
+
 FOXP3
+
 Treg cells based on 
gender per group, Relationship between the duration of 
remission after treatment with sHLA-G levels and 
frequency of Treg cells, correlation between sHLA-G 
and Treg cells with age of patients and control group 
which are shown in Table 2. After measuring sHLA-G 
in participants, Treg cells were measured in subjects 
with cut off of sHLA-G≥10 U/ml (Mean of 100 results 
of healthy subjects +3SEM.Because there wasn’t 
normal range or cut off for soluble HLA-G.) (Table 2). 
In addition, treated patients (n=132) were divided 
into two groups according to their duration of remission 
after treatment: remission less than one year and more 
than one year. The results showed that sHLA-G levels 
were lower in patients who had remission in less than 
one year compared to patients with remission in more 
than one year (p=0.040 This comparison was not 
significant for  CD4
+
 CD25
+
 FOXP3
+
 Treg cells. 
Furthermore, sHLA-G and CD4
+
 CD25
+
 FOXP3
+
 Treg 
cell frequency decreased with long time treatment 
(ρsHLA-G=-0.245 , ρTreg=-0.183) (Table 2).   
Our results showed a significant difference between 
RRMS patients (n=21) in Treg cells frequency in 
comparison to healthy controls (n=7) (p=0.048) 
(Figure. 2a).We assesed the concetration of sHLA-G in 
treated and untreated RRMS patients compared to 
healthy contols. Data showed a signifiant difference for  
sHLA-G  levels in the three groups of control, treated 
and untreated patients (p<0.05). This relation was more 
significant between control vs. treated patients 
(p<0.000) and control vs. untreated patients 
(P<0.000)(Figure.2b). On the other hand results were 
not significant in treated patients by IFN-β vs. 
untreated subjects (P=0.127).  
 
 
Table 1. Demographic features of RRMS patients (n=205) 
and healthy controls (n=205) 
Demographic RRMSs(Cases)          HCs(Controls) 
Age (Mean±SD) 31.32±8.53 32.2±7.48 
Gender   
Male 37(18%) 39(19%) 
Female 168(82%) 166(81%) 
 
 
Table 2. Laboratory Findings of RRMS patients and healthy controls and Mean of sHLA-G and Treg according to gender 
and in correlation with age in both groups (n= 205).  
sHLA-G Gender 
RRMS (Cases) 
P Value 
HC 
(Controls) P Value 
(n=205) (n=205) 
 Male 3.54±0.75 0.703 6.10±1.20 0.009 
Female 3.94±0.38 3.20±0.37 
 Female/Male Ratio 4.54  4.26  
CD4+ CD25+ FOXP3+Treg Gender       (n=21) 0.837 (n=7) 0.047 
Male 6.93±0.87 2.64±0.52 
Female 7.28±0.93 6.48±1.91 
Female/Male Ratio 4.25 0.75 
sHLA-G remission ≤ 1 year 3.48±0.41 0.040 - - 
 > 1 year 6.89±1.51 - 
Treg remission ≤ 1 year 8.12±1.36 0.590 - - 
  > 1 year 7.06±0.58 - - 
sHLA-G/ Treg(Correlation) remission  -0.245 0.034 - - 
  -0.183 0.483 - - 
sHLA-G/ Treg(Correlation  ) Age  -0.211 0.002 -0.150 0.041 
  0.011 0.853 0.322 0.482 
Data analysis showed that there were significant differences on sHLA-G level and Treg frequency according to gender in healthy subjects while this 
was not the same in RRMS patients. Age was effective on sHLA-G  level in RRMS (p=0.002) and healthy subjects )p=0.041) but Kruskal-Wallis test 
did not show significant differences on age and Treg frequency in the two groups (p=0.482). Pearson correlation test indicated that age had an inverse 
relation with sHLA-G  level and Treg frequency in both groups. There were also significant differences in the levels of sHLA-G in patients who had 
less than 1 year of remission compared to patients who had more than one year remmision. 
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(a) 
 
(b)  
      
(C) 
 
 
Figure 2. Comparison sHLA-G level and Treg frequency in RRMS patients and healthy controls (HC). (a) sHLA-G levels 
compared to  RRMS (n=205) and  HC (n=205), Treg frequency compared to  RRMS (n=21) and  HC(n=7), (b): sHLA-G level, 
in RRMS patients stratified according to treated (n=132), untreated   patients(n=73) and HC (n=205) and Treg frequency in 
RRMS patients who had sHLA-G≥ 10 U which was stratified according to treated (n=16), untreated patients(n=5) and HCs 
(n=7). (c) Treg frequency in subjects who had sHLA-G ≥ 10 U/ml in untreated (n=5) , treated  patients (n=16) and HCs (n=7) 
 
We also examined the frequency of Treg cells in the 
three groups (control, treated and untreated patients). 
Treg values showed generally non-signifiant 
relationship in the three groups (p>0.05). Howover, the 
data showed a significant relevance for Treg cells in 
control vs. treated patients (p=0.029), which was in 
contrast to the control vs untreated patients (p=0.530) 
wheras it did not indicate significant diffrence between 
treated vs. untreated patients (Figure 2b). 
In adddition, we found  that there was signifiant 
relationship between sHLA-G and Treg frequency in 
treated patients (n=16) and healthy subjects (n=7) who 
had sHLA-G ≥10 U/ml (p=0.029) (Figure 2c).  
Besides, the gender parameter was effective on 
sHLA-G levels and Treg frequency in healthy controls, 
while the sHLA-G  levels of males in comparison to 
females was higher only in healthy individuals. Also, 
age was effective on sHLA-G  level in RRMS patients 
(p=0.002) and healthy subjects (p=0.041) (Table 2). 
These data showed an inverse relationship between age 
and sHLA-G, age and Treg in both case and control 
groups (p<0.05). 
 
DISCUSSION 
 
In our current research, we analyzed the 
involvement of sHLA-G molecules in the stable phase 
of Iranian RRMS patients in comparison with healthy 
subjects. In this investigation, sHLA-G level indicated 
a significant difference in treated patients compared to 
healthy subjects. Our data were in line with the other 
findings which have found a link between levels of 
serum sHLA-G antigen and disease course in MS 
patients.
22
 Mitsdoerffer et al demonstrated that the 
sHLA-G antigen, arised from monocytes, inhibited 
both secretion of Th1 and Th2 related cytokines and 
could potentially have immuneregulatory role in 
pathogenesis of MS.
22
 
sHLA-G generates a tolerogenic phenotype in 
myeloid dendritic cells through binding to 
immunoglobulin-like transcript 4 receptor (ILT4) 
which results in induction of Treg cells.
19
 Similarly, we 
observed the correlation between Treg frequency and 
sHLA-G level in both healthy subjects and treated 
patients with sHLA-G≥10 U/ml.This study showed the 
high levels of sHLA-G in treated patients which agreed 
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with the results of Mitsdoerffer′s study.23 Since, sHLA-
G molecules have diverse functions, their measurement 
as a plasma biomarker could establish an individualized 
treatment.  
In addition, this study did not find any differences 
in the frequency of CD4
+
 CD25
high
 Foxp3
+
cells  
between untreated RRMS patients and  healthy  
individuals. This finding was in agreement with some 
studies
24-28
 but  in contrast to the study of Kumar et al.
29
 
which reported significantly increased Treg cells 
(CD3
+
CD4
+
CD25
+
) in whole  blood of untreated MS 
patients compared to healthy individuals. The 
difference could be related to the type of selective 
markers that were considered as Treg and because of 
technical issues. However, a recent study showed 
reduced relative counts of CD4
+
CD25
+
 T cells in 
untreated RRMS patients compared to  healthy  
controls.
30
 The possible explanation could be different 
subgroup and populations analysed.  
Different  researches have shown controversial results 
related to Treg frequency in MS patients compared to 
healthy subjects. First, some studies have shown that 
the number of  CD4+ CD25high Treg cells is not 
significantly different in MS  patients and HCs.28 
Second, inappropriate peripheral homeostasis of Tregs 
Could explain the lower Treg numbers and leading to 
evading autoaggressive  T cells. Some reports explain 
an age-suboptimal decrease in changed T-cell 
homeostasis in a subset of  MS patients.
31
 A detailed 
analysis of parameters related to Treg cells in MS 
patients is necessary to investigate this possibility. 
Since both sHLA-G and Treg have modulator 
properties in the immune system, another aspect of our 
study was to clarify whether sHLA-G is related with 
the frequency of Treg cells. The present study found 
that Treg cell frequency was significantly higher in 
treated MS patients who had sHLA-G level≥ 10 U/ml 
vs. healthy subjects. Similarity, other studies have 
shown that in healthy subjects the number of HLA-G
+
 
Treg cells was few in the peripheral blood, but they 
increased in the inflammation sites like CNS.
32
 
In this study, the gender parameter was effective on 
sHLA-G level and frequency of Treg cells in the 
control group, but in patients
‘ 
group, the gender 
parameter was not effective. In fact, sHLA-G level in 
male participants of the control group was higher than 
females. This finding did not agree with other studies 
which could be due to different studied populations.
33
 
Treg frequency of the control group was higher in 
females compared to males. On the other hand, age 
parameter showed a significant relationship with 
sHLA-G level in the two groups, while age showed an 
inverse effect on Treg frequency in the two groups. 
While, Gregg et al. have shown that increasing of 
CD4
+
CD25
hi 
Treg cells associated with ageing in 
healthy volunteers.
32
 
In this research, sHLA-G level in the control group 
less than 10 years old was higher than other age groups. 
In this regard, Fainardi E et al demonstrated no 
relationship between age parameter and sHLA-G level 
but they noted higher sHLA-G levels in females than 
males.
22
 Differences in the analysis method used could 
in part explain the reported discrepancy. The frequency 
of Treg in patients’ age groups (age: 30-40 years) and 
in control group (age: 10-20 years) were higher than 
other age groups. Overall, these differences could be 
due to the putative autoantigen diversity in MS disease 
and perhaps to be patient-specific owing to epitope 
spreading with disease progression and differences in 
genetic background.
34
 
In conclusion, our data suggests the increasing of 
sHLA-G >10 U/ml may influence Treg cell frequency 
which subsequently leads to induce stable phase in 
RRMS patients.We suggest, in the early phase of the 
disease, a reduction in Treg frequency and their 
function caused by either genetic alterations or reduced 
thymic Treg output could give rise to suboptimal 
peripheral tolerance, leading to escape of 
autoaggressive T cells. Further investigations should be 
done to resolve these issues possibly performed in the 
CNS. 
 
ACKNOWLEDGEMENTS 
 
This work is supported in part by the research 
center of Tarbiat Modares University. We thank the 
Isfahan MS and Neuroimmunology Research Centers. 
We are grateful to all patients and volunteers who 
participated in this study and appreciate Dr Nahid 
Eskandari and Dr Mohadase
 
Behjati for critical 
comments on this article. 
 
REFERENCES 
 
1. Lin R, Taylor BV, Simpson S Jr, Charlesworth J, 
Ponsonby AL, Pittas F, et al. Association between 
multiple sclerosis risk-associated SNPs and relapse and 
disability - a prospective cohort study. Mult Scler 2013; 
20(3):313-21. 
F. Alsahebfosoul, et al 
304/ Iran J Allergy Asthma Immunol, Spring 2015                                Vol. 14, No. 3, June 2015 
   Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
2. International Multiple Sclerosis Genetics Consortium. 
The genetic association of variants in CD6, TNFRSF1A 
and IRF8 to multiple sclerosis: a multicenter case-control 
study. PLoS One 2011; 6(4):e18813. 
3. Reich D1, Patterson N, De Jager PL, McDonald GJ, 
Waliszewska A, Tandon A, et al. A whole-genome 
admixture scan finds a candidate locus for multiple 
sclerosis susceptibility. Nat Genet 2005; 37(10):1113-8. 
4. Martino G, Furlan R, Poliani PL. [The pathogenic role of 
inflammation in multiple sclerosis]. Rev Neurol 2000; 
30(12):1213-7. 
5. Lukas C, Sombekke MH, Bellenberg B, Hahn HK, 
Popescu V, Bendfeldt K, et al. Relevance of spinal cord 
abnormalities to clinical disability in multiple sclerosis: 
MR imaging findings in a large cohort of patients. 
Radiology 2013; 269(2):542-52. 
6. Poser CM, Brinar VV. Diagnostic criteria for multiple 
sclerosis. Clin Neurol Neurosurg 2001; 103(1):1-11. 
7. Daria Bortolotti, V.G., Antonella Rotola, Enzo Cassai, 
Roberta Rizzo, Dario Di Luca, Impact of HLA-G analysis 
in prevention, diagnosis and treatment of pathological 
conditions. World Journal of W J M Methodology 2014; 
4(1):11-25. 
8. Kirszenbaum M, Moreau P, Gluckman E, Dausset J, 
Carosella E. An alternatively spliced form of HLA-G 
mRNA in human trophoblasts and evidence for the 
presence of HLA-G transcript in adult lymphocytes. Proc 
Natl Acad Sci U S A 1994; 91(10):4209-13. 
9. Fujii T, Ishitani A, Geraghty DE. A soluble form of the 
HLA-G antigen is encoded by a messenger ribonucleic 
acid containing intron 4. J Immunol 1994; 153(12): p. 
5516-24. 
10. Fujii T, Ishitani A, Geraghty DE. Geraghty, A soluble 
form of the HLA-G antigen is encoded by a messenger 
ribonucleic acid containing intron 4. J Immunol 1994; 
153(12):5516-24. 
11. Poláková K, Bandžuchová E, Russ G. Impact of blood 
processing on estimation of soluble HLA-G. Neoplasma 
2011; 58(4):337-42. 
12. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-
G: Are they clinically relevant? Semin Cancer Biol 2007; 
17(6):469-79. 
13. Chen CH, Liao HT, Chen HA, Liu CH, Liang TH, Wang 
CT, et al. Human leukocyte antigen-G in ankylosing 
spondylitis and the response after tumour necrosis factor-
alpha blocker therapy. Rheumatology (Oxford) 2010; 
49(2):264-70. 
14. Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, 
Vasquez A, et al. Soluble HLA-G inhibits cell cycle 
progression in human alloreactive T lymphocytes. J 
Immunol 2006; 176(3):1331-9. 
15. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, 
Colonna M, Braud VM, et al. Human inhibitory receptors 
Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 
for MHC class I binding and bind preferentially to HLA-
G. Proc Natl Acad Sci U S A 2003; 100(15):8856-61. 
16. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone 
S, et al. Soluble HLA-A,-B,-C and -G molecules induce 
apoptosis in T and NK CD8+ cells and inhibit cytotoxic T 
cell activity through CD8 ligation. Eur J Immunol 2003; 
33(1):125-34. 
17. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, 
Carosella ED. Soluble HLA-G protein secreted by allo-
specific CD4+ T cells suppresses the allo-proliferative 
response: a CD4+ T cell regulatory mechanism. Proc Natl 
Acad Sci U S A 2001; 98(21):12150-5. 
18. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, 
Carosella ED. HLA-G2, -G3, and -G4 isoforms expressed 
as nonmature cell surface glycoproteins inhibit NK and 
antigen-specific CTL cytolysis. J Immunol 2001; 
166(8):5018-26. 
19. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella 
ED. HLA-G1-expressing antigen-presenting cells induce 
immunosuppressive CD4+ T cells. Proc Natl Acad Sci U 
S A 2004; 101(18):7064-9. 
20. Waschbisch A, Sandbrink R, Hartung HP, Kappos L, 
Schwab S, Pohl C, et al. Evaluation of soluble HLA-G as 
a biomarker for multiple sclerosis. Neurology 2011; 
77(6):596-8. 
21. Zozulya AL, Wiendl H. The role of regulatory T cells in 
multiple sclerosis. Nat Clin Pract Neurol 2008; 4(7):384-98. 
22. Fainardi E, Rizzo R, Melchiorri L, Stignani M, 
Castellazzi M, Caniatti ML, et al. Soluble HLA-G 
molecules are released as HLA-G5 and not as soluble 
HLA-G1 isoforms in CSF of patients with relapsing-
remitting multiple sclerosis. J Neuroimmunol 2007; 
192(1-2):219-25. 
23. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, 
Dichgans J, Hartung HP, et al. Monocyte-derived HLA-G 
acts as a strong inhibitor of autologous CD4 T cell 
activation and is upregulated by interferon-beta in vitro 
and in vivo: rationale for the therapy of multiple sclerosis. 
J Neuroimmunol 2005; 159(1-2):155-64. 
24. Putheti P, Pettersson A, Soderstrom M, Link H, Huang 
YM. Circulating CD4+CD25+ T regulatory cells are not 
altered in multiple sclerosis and unaffected by disease-
modulating drugs. J Clin Immunol 2004; 24(2):155-61. 
Soluble HLA-G Isoforms and Regulatory T Cells in Multiple Sclerosis 
Vol. 14, No. 3, June 2015                                                                                                                 Iran J Allergy Asthma Immunol, Spring 2015 /305 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
25. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. 
Loss of functional suppression by CD4+CD25+ 
regulatory T cells in patients with multiple sclerosis. J 
Exp Med 2004; 199(7):971-9. 
26. Fritzsching B, Oberle N, Eberhardt N, Quick S, Haas J, 
Wildemann B, et al. In contrast to effector T cells, 
CD4+CD25+FoxP3+ regulatory T cells are highly 
susceptible to CD95 ligand- but not to TCR-mediated cell 
death. J Immunol 2005; 175(1):32-6. 
27. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, 
Wiendl H. Increased frequency of CD4+ CD25+ 
regulatory T cells in the cerebrospinal fluid but not in the 
blood of multiple sclerosis patients. Clin Exp Immunol 
2007(147 ):412–8. 
28. Venken K, Hellings N, Hensen K, Rummens JL, Medaer 
R, D'hooghe MB, et al. Secondary progressive in contrast 
to relapsing-remitting multiple sclerosis patients show a 
normal CD4+CD25+ regulatory T-cell function and 
FOXP3 expression. J Neurosci Res 2006; 83(8):1432-46. 
29. Kumar M, Putzki N, Limmroth V, Remus R, Lindemann 
M, Knop D, et al. CD4+CD25+FoxP3+ T lymphocytes 
fail to suppress myelin basic protein-induced proliferation 
in patients with multiple sclerosis. J Neuroimmunol 2006; 
180(1-2):178-84. 
30. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, 
Weiner HL. CHanges in activated t cells in the blood 
correlate with disease activity in multiple sclerosis. Arch 
Neurol 2000; 57(8):1183-9. 
31. Duszczyszyn DA, Beck JD, Antel J, Bar-Or A, Lapierre 
Y, Gadag V, et al. Altered naive CD4 and CD8 T cell 
homeostasis in patients with relapsing-remitting multiple 
sclerosis: thymic versus peripheral (non-thymic) 
mechanisms. Clin Exp Immunol 2006; 143(2):305-13. 
32. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, 
Chakraverty R, et al. The number of human peripheral 
blood CD4+ CD25high regulatory T cells increases with 
age. Clin Exp Immunol 2005; 140(3):540-6. 
33. Rebmann V, Pfeiffer K, Pässler M, Ferrone S, Maier S, 
Weiss E, et al. Detection of soluble HLA-G molecules in 
plasma and amniotic fluid. Tissue Antigens 1999; 
53(1):14-22. 
34. Abediankenari S, Farzad F, Rahmani Z, and Hashemi-
soteh MB. HLA-G in pregnant women: HLA-G5 and G7 
Isoforms in Pregnant Women, IJAAI, In press. 
 
